Objective: To assess the influence of intensive insulin therapy (IIT), as compared with conventional insulin therapy (CIT), on mortality of critically ill patients in the intensive care unit (ICU) by Meta-analysis.
Methods: Computer retrieval was conducted to search for randomly controlled trials (1966-2009) to compare the result of IIT and CIT. The quality of included studies was critically evaluated and data were analyzed by using the Cochrane Collaboration's RevMan 5.0 software.
Results: A total of 23 studies were included in the Meta-analyses, consisting 11 216 patients. This Meta-analysis showed that there were significant difference between IIT and CIT in the mortality (unselected in the medical, surgical and mixed ICU), with significant lowering in IIT group. There was remarkable lowering of infection rate and the complication rate in IIT group compared with CIT group. However, the incidence of hypoglycemia was slightly lower in CIT group.
Conclusion: IIT tends to lower the mortality rate, infection rate, and complications in critically ill patients in the ICU as compared with CIT. Also with IIT the target blood glucose can be easier reached than CIT. The therapy can improve the quality of life. However, IIT is not as good as CIT in the control of hypoglycemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Antibacterial and osteogenic properties of chitosan-polyethylene glycol nanofibre-coated 3D printed scaffold with vancomycin and insulin-like growth factor-1 release for bone repair.
Int J Biol Macromol
January 2025
Materials Engineering Group, Golpayegan College of Engineering, Isfahan University of Technology, Golpayegan 87717-67498, Iran.
3D printing, as a layer-by-layer manufacturing technique, enables the customization of tissue engineering scaffolds. Surface modification of biomaterials is a beneficial approach to enhance the interaction with living cells and tissues. In this research, a polylactic acid/polyethylene glycol scaffold containing 30 % bredigite nanoparticles (PLA/PEG/B) was fabricated utilizing fused deposition modeling (FDM) 3D printing.
View Article and Find Full Text PDFEfficacy and safety of olive leaf extract (Olea europaea L.) for glycaemic control in adults with type 2 diabetes mellitus (ESOLED): A pilot randomised controlled trial.
Complement Ther Clin Pract
January 2025
Faculty of Health & Education, Torrens University Australia, Bowen Terrace, Fortitude Valley, QLD, 4006, Australia.
Background: Maintaining optimum glycaemic control is essential to reducing comorbidity and mortality in diabetes. However, research indicates that <50 % of patients achieve their target HbA1c ranges. Laboratory studies suggest that olive leaf extract (OLE) may improve glycaemic control, however clinical studies in persons with diabetes are lacking.
View Article and Find Full Text PDFCurrent perspectives and the future of disease-modifying therapies in type 1 diabetes.
World J Diabetes
January 2025
Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.
Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.
View Article and Find Full Text PDFEfficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.
World J Diabetes
January 2025
Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Background: There is a lack of clinical evidence on the efficacy and safety of transitioning from a thrice-daily pre-mixed insulin or basal-prandial regimen to insulin deglu-dec/aspart (IDegAsp) therapy, with insufficient data from the Chinese popu-lation.
Aim: To demonstrate the efficacy, safety, and treatment satisfaction associated with the transition to IDegAsp in type 2 diabetes mellitus (T2DM).
Methods: In this 12-week open-label, non-randomized, single-center, pilot study, patients with T2DM receiving thrice-daily insulin or intensive insulin treatment were transitioned to twice-daily injections of insulin IDegAsp.
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report.
World J Diabetes
January 2025
Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China.
Background: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients.
Case Summary: This report describes an 83-year-old female patient with a 30-year history of type 2 diabetes (T2DM) who had struggled to control her blood sugar for more than a year. She had a history of high blood pressure for 30 years, had undergone continuous ambulatory peritoneal dialysis for more than two years, was 163 cm tall, weighed 77 kg, and had a body mass index of 28.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!